Monument Capital Management Has $245,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Monument Capital Management trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 27.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,497 shares of the biopharmaceutical company’s stock after selling 3,180 shares during the quarter. Monument Capital Management’s holdings in Pfizer were worth $245,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc acquired a new stake in Pfizer during the third quarter valued at approximately $30,000. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer during the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC boosted its holdings in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC boosted its holdings in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer during the fourth quarter valued at approximately $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Performance

PFE stock opened at $26.26 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a 50 day moving average price of $27.08 and a 200 day moving average price of $28.56. Pfizer Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $40.37. The stock has a market capitalization of $148.70 billion, a PE ratio of 72.94, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the company posted $1.14 EPS. Pfizer’s revenue was down 41.3% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.